Subsequent identification of TTF-1 positivity and an EGFR exon 19 deletion confirmed the diagnosis of metastatic lung adenocarcinoma to the pancreas, enabling appropriate targeted therapy. Our experience highlights the importance of considering molecular discordance when evaluating patients with multiple lesions and demonstrates how targeted molecular testing can guide appropriate diagnosis in complex oncological cases. This evidence concerns the gene EGFR and lung adenocarcinoma.